Poster published at ISPOR EU 2009. Analysis examining the association of HRQoL and relapses that occurred in the previous year among MS patients, using data from the Real-World Betaseron® Outcomes Study (ROBUST); ROBUST is a 12-month, US, prospective, observational, open-label, single-arm, multi-center outcomes study of interferon beta-1b given every other day for MS.